A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 20, Issue -, Pages 34-46
Publisher
Wiley
Online
2018-01-25
DOI
10.1111/dom.13135
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period
- (2017) Takashi Kadowaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study
- (2017) Karen E. Elkind-Hirsch et al. FERTILITY AND STERILITY
- Effect of Linagliptin on Arterial 18 F-Fluorodeoxyglucose Positron Emission Tomography Uptake
- (2017) Stefanie A. de Boer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial
- (2017) Francisco J Pasquel et al. Lancet Diabetes & Endocrinology
- Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
- (2017) Feng-fei Li et al. Diabetes Therapy
- Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
- (2017) Takuya Awata et al. Diabetes Therapy
- Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
- (2017) Feng-fei Li et al. Diabetes Therapy
- Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
- (2017) Takuya Awata et al. Diabetes Therapy
- Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
- (2016) Kristy Iglay et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)
- (2016) Tomoya Mita et al. DIABETES CARE
- Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2016) Lennart Tonneijck et al. DIABETES CARE
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial
- (2016) Masanori Abe et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes
- (2016) S. Durán-Garcia et al. DIABETIC MEDICINE
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
- (2016) Christian Ott et al. DIABETOLOGIA
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction — Long-term results of the SITAGRAMI trial
- (2016) Lisa Gross et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease
- (2016) Shingo Kato et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study
- (2016) Inbal Goldshtein et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
- (2016) Satoru Takashima et al. KIDNEY INTERNATIONAL
- Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes
- (2016) Feng-fei Li et al. MEDICINE
- A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
- (2016) Kristian B. Filion et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial
- (2016) Maeve Lynch et al. Trials
- Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes
- (2016) Ying Cao et al. Journal of Diabetes
- The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial
- (2016) Jun-ichi Oyama et al. PLOS MEDICINE
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
- (2016) Darren K. McGuire et al. JAMA Cardiology
- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
- (2015) Julio Rosenstock et al. Cardiovascular Diabetology
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
- (2015) Aijaz Ahmed et al. Clinical Gastroenterology and Hepatology
- Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
- (2015) Theodora Nakouti et al. Current Vascular Pharmacology
- Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease
- (2015) Janet B McGill et al. Diabetes & Vascular Disease Research
- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
- (2015) Nikolaus Marx et al. Diabetes & Vascular Disease Research
- Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
- (2015) Tomoya Mita et al. DIABETES CARE
- Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
- (2015) Lawrence A. Leiter et al. DIABETES CARE
- Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes
- (2015) S. E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients
- (2015) G. McInnes et al. DIABETES OBESITY & METABOLISM
- Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
- (2015) Hiroyuki Kato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
- (2015) Wolfgang Kothny et al. DIABETOLOGIA
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy
- (2015) Eunsoo Jung et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin
- (2015) Masao Moroi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
- (2015) Andrea Tura et al. International Journal of Endocrinology
- The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin—The Sit2Mix trial
- (2015) Sultan Linjawi et al. Primary Care Diabetes
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
- (2015) Chantal Mathieu et al. Diabetes Therapy
- A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
- (2015) Chantal Mathieu et al. Diabetes Therapy
- Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial
- (2015) Seiji Sato et al. PLoS One
- Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
- (2014) Nayyar Iqbal et al. Cardiovascular Diabetology
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
- (2014) Liam M. McCormick et al. Circulation-Cardiovascular Imaging
- Incretin-Based Drugs and the Risk of Congestive Heart Failure
- (2014) Oriana Hoi Yun Yu et al. DIABETES CARE
- Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes
- (2014) J. Farngren et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase
- (2014) Kohei Kaku et al. EXPERT OPINION ON PHARMACOTHERAPY
- Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
- (2014) Yuliya Sharkovska et al. JOURNAL OF HYPERTENSION
- Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study
- (2013) Shigemasa Tani et al. American Journal of Cardiovascular Drugs
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
- (2013) M. Barbieri et al. ATHEROSCLEROSIS
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
- (2013) Anthony H. Barnett et al. CLINICAL DRUG INVESTIGATION
- Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes: A pilot, randomized, controlled study
- (2013) G. E. Umpierrez et al. DIABETES CARE
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Type 2 Diabetes
- (2013) Jaime Davidson Endocrine Practice
- Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
- (2013) Anthony H Barnett et al. LANCET
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
- (2013) Hiroko Mori et al. Journal of Diabetes Investigation
- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study
- (2012) E. S. Hong et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline
- (2012) Guillermo E. Umpierrez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
- (2011) Cristina Mega et al. Experimental Diabetes Research
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial
- (2010) P. Hollander et al. DIABETES OBESITY & METABOLISM
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now